Stifel Reiterates Buy on Mirati Therapeutics, Maintains $83 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Benjamin Burnett has reiterated a 'Buy' rating on Mirati Therapeutics (NASDAQ:MRTX) and maintained a price target of $83.
October 06, 2023 | 3:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst has reiterated a 'Buy' rating on Mirati Therapeutics and maintained a price target of $83.
The reiteration of a 'Buy' rating by a Stifel analyst and the maintenance of a price target of $83 indicates a positive outlook for Mirati Therapeutics. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100